OTCPK:OXNX.F

Stock Analysis Report

Executive Summary

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide.

Risk Analysis

Earnings are forecast to decline by an average of -16.4% per year for the next 3 years

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Latest financial reports are more than 6 months old

+ 2 more risks


Snowflake Analysis

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has Onxeo's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OXNX.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

OXNX.F

-0.3%

US Biotechs

0.9%

US Market


1 Year Return

n/a

OXNX.F

12.4%

US Biotechs

20.0%

US Market

Return vs Industry: Insufficient data to determine how OXNX.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how OXNX.F performed against the US Market.


Shareholder returns

OXNX.FIndustryMarket
7 Day0%-0.3%0.9%
30 Day0%0.9%1.4%
90 Dayn/a8.5%8.8%
1 Yearn/a13.3%12.4%22.5%20.0%
3 Yearn/a22.8%19.5%49.9%40.3%
5 Yearn/a3.1%-1.7%73.2%54.1%

Price Volatility Vs. Market

How volatile is Onxeo's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Onxeo undervalued compared to its fair value and its price relative to the market?

0.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OXNX.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OXNX.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OXNX.F is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OXNX.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OXNX.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OXNX.F is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Onxeo forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-16.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXNX.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OXNX.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OXNX.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OXNX.F's revenue is expected to decline over the next 3 years (-33.7% per year).

High Growth Revenue: OXNX.F's revenue is forecast to decline over the next 3 years (-33.7% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OXNX.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Onxeo performed over the past 5 years?

-17.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OXNX.F is currently unprofitable.

Growing Profit Margin: OXNX.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OXNX.F is unprofitable, and losses have increased over the past 5 years at a rate of -17.6% per year.

Accelerating Growth: Unable to compare OXNX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXNX.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: OXNX.F has a negative Return on Equity (-23.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Onxeo's financial position?


Financial Position Analysis

Short Term Liabilities: OXNX.F's short term assets (€13.4M) exceed its short term liabilities (€7.9M).

Long Term Liabilities: OXNX.F's short term assets (€13.4M) exceed its long term liabilities (€12.1M).


Debt to Equity History and Analysis

Debt Level: OXNX.F's debt to equity ratio (19%) is considered satisfactory.

Reducing Debt: OXNX.F's debt to equity ratio has increased from 0.2% to 19% over the past 5 years.


Balance Sheet

Inventory Level: OXNX.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: OXNX.F's debt is covered by short term assets (assets are 1.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OXNX.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OXNX.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.1% each year


Next Steps

Dividend

What is Onxeo's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OXNX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OXNX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OXNX.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OXNX.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OXNX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Judith Greciet (51yo)

8.7yrs

Tenure

€550,681

Compensation

Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Operation ...


CEO Compensation Analysis

Compensation vs Market: Judith's total compensation ($USD596.62K) is about average for companies of similar size in the US market ($USD521.92K).

Compensation vs Earnings: Judith's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Judith Greciet
CEO & Director8.7yrs€550.68k0.19% 68.5k
Nicolas Fellmann
CFO & Administrative and Finance Director13.3yrsno datano data
Françoise Bono
Chief Scientific Officer2.9yrsno datano data
Audrey Legentil-Dumery
Director of Human Resources5yrsno datano data
Michel Forest
Chief Pharmacist & Quality Assurance Director0yrsno datano data
Philippe Maitre
Chief of US Operations & Executive VP3.9yrsno datano data
Olivier de Beaumont
Chief Medical Officer2.9yrsno datano data

4.5yrs

Average Tenure

51yo

Average Age

Experienced Management: OXNX.F's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Judith Greciet
CEO & Director8.7yrs€550.68k0.19% 68.5k
Thomas Hofstaetter
Independent Director7.8yrs€13.95kno data
Jean-Pierre Kinet
Independent Director3.8yrs€9.45kno data
Tomas Lindahl
Chairman of Scientific Advisory Board2.3yrsno datano data
Christine Garnier
Independent Director2.8yrs€10.45kno data
Marie Dutreix
Member of Scientific Advisory Board2.3yrsno datano data
Jean-Pierre Bizzari
Independent Director3.8yrs€8.20kno data
Nicolas Trebouta
Representative Director8.7yrsno data0.066% 24.2k
Danièle Guyot-Caparros
Independent Chairman0.8yrs€10.95k0.062% 22.5k
Elvira Urgoiti
Independent Director2.8yrs€11.45kno data

3.3yrs

Average Tenure

60.5yo

Average Age

Experienced Board: OXNX.F's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

Onxeo SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Onxeo SA
  • Ticker: OXNX.F
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €33.615m
  • Listing Market Cap: €36.419m
  • Shares outstanding: 61.01m
  • Website: https://www.onxeo.com

Number of Employees


Location

  • Onxeo SA
  • 49, boulevard du Général Martial Valin
  • Paris
  • Ile-de-France
  • 75015
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONXEOENXTPA (Euronext Paris)YesOrdinary SharesFREURDec 2005
C4XDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2005
0NWKLSE (London Stock Exchange)YesOrdinary SharesGBEURDec 2005
OXNX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2005
ONXEOCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKDec 2005
ONXEOPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURDec 2005

Biography

Onxeo SA, a biotechnology company, develops drugs for the treatment of orphan oncology diseases worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in clinical development stage for the treatment of metastatic melanoma; and Validive, which completed Phase II clinical trial for the treatment of serious mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is based in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/18 00:45
End of Day Share Price2019/12/30 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.